Hematopoietic stem cell transplantation for CTLA4 deficiency.
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom. Electronic address: mary.slatter@nuth.nhs.uk.
Mary A
MA
Slatter
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Karin R
KR
Engelhardt
University of Washington and Seattle Children's Hospital, Seattle, Wash; Fred Hutchinson Cancer Research Center, Seattle, Wash.
Lauri M
LM
Burroughs
University of Manchester, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Peter D
PD
Arkwright
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom.
Zohreh
Z
Nademi
University of Washington and Seattle Children's Hospital, Seattle, Wash.
Suzanne
S
Skoda-Smith
University of Washington and Seattle Children's Hospital, Seattle, Wash.
David
D
Hagin
UCL Institute of Immunity and Transplantation, Royal Free Hospital, London, United Kingdom.
Alan
A
Kennedy
Regional Immunology Laboratory, Newcastle upon Tyne, United Kingdom.
Dawn
D
Barge
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Terence
T
Flood
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom.
Mario
M
Abinun
University of Manchester, Royal Manchester Children's Hospital, Manchester, United Kingdom.
Robert F
RF
Wynn
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom.
Andrew R
AR
Gennery
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom.
Andrew J
AJ
Cant
UCL Institute of Immunity and Transplantation, Royal Free Hospital, London, United Kingdom.
David
D
Sansom
Great North Children's Hospital, Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle upon Tyne University, Newcastle upon Tyne, United Kingdom.
Sophie
S
Hambleton
University of Washington and Seattle Children's Hospital, Seattle, Wash.
Troy R
TR
Torgerson
D000293:Adolescent; D000328:Adult; D019943:Amino Acid Substitution; D060908:CTLA-4 Antigen / Q000172:deficiency* / Q000235:genetics* / Q000276:immunology; D002648:Child; D005260:Female; D016368:Frameshift Mutation; D057895:Haploinsufficiency / Q000235:genetics / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007154:Immune System Diseases / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D008297:Male; D009154:Mutation; D020125:Mutation, Missense; D016896:Treatment Outcome
D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human